

WALLEN WILLIAM C  
Form 4  
July 31, 2009

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
WALLEN WILLIAM C

2. Issuer Name and Ticker or Trading Symbol  
IDEXX LABORATORIES INC /DE [IDXX]

5. Relationship of Reporting Person(s) to Issuer  
(Check all applicable)

(Last) (First) (Middle)  
C/O IDEXX LABORATORIES INC, ONE IDEXX DRIVE  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
07/29/2008

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
SVP & Chief Scientific Officer

WESTBROOK, ME 04092

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |   |        | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |            |       |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--------|---|--|-----------------------------------|------------|-------|
|                                 |                                      |  |                                | Code  | V | Amount |   |  |                                   | (A) or (D) | Price |
| Common Stock                    | 07/29/2009                           |  | M                              |   |   | 15,000 | A   | \$ 21.3  | 32,114 <sup>(2)</sup>             | D          |       |
| Common Stock                    | 07/29/2009                           |  | S                              |   |   | 15,000 | D   | \$ 49.7397 <sup>(1)</sup>                                | 17,114                            | D          |       |
| Common Stock                    | 07/29/2009                           |  | M                              |   |   | 1,500  | A   | \$ 21.3  | 18,614                            | D          |       |
| Common Stock                    | 07/30/2009                           |  | M                              |   |   | 5,000  | A   | \$ 21.3  | 23,614                            | D          |       |
|                                 | 07/30/2009                           |  | S                              |   |   | 5,000  | D   | \$ 49.8  | 18,614                            | D          |       |

Common  
Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) | Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|----------------------------|
| Incentive Option (right to buy)            | \$ 21.3  | 07/29/2009                           |  | M                              | 1,500   | (3) 09/08/2013   | Common Stock  | 1,500                      |
| Non-Qualified Stock Option (right to buy)  | \$ 21.3  | 07/29/2009                           |  | M                              | 15,000  | (3) 09/08/2013   | Common Stock  | 15,000                     |
| Non-Qualified Stock Option (right to buy)  | \$ 21.3  | 07/30/2009                           |  | M                              | 5,000   | (3) 09/08/2013   | Common Stock  | 5,000                      |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |                                |       |
|--|---------------|-----------|--------------------------------|-------|
|  | Director      | 10% Owner | Officer                        | Other |
| WALLEN WILLIAM C<br>C/O IDEXX LABORATORIES INC<br>ONE IDEXX DRIVE<br>WESTBROOK, ME 04092 |               |           | SVP & Chief Scientific Officer |       |

## Signatures

John B. Rogers, Attorney-in-Fact for William C. Wallen, PhD

07/31/2009

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- The sales price reported above reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged
- (1) between \$49.65 and \$49.85. Reporting person hereby undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
  - (2) Includes 110 shares of common stock acquired pursuant to the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2009.
  - (3) Grant of options to purchase shares of common stock becomes exercisable in five equal increments, beginning on the first anniversary date (9/8/2004) of the date of the grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.